IL12RB1 and neoplasm: The second immune‐based therapy that we tested, IL‐12, is predicted to enhance anti‐tumor T‐cell response by two mechanisms: stimulating T cells directly through its receptor IL‐12R and by protecting T cells from IFN‐γ mediated negative regulation by downregulating checkpoint expression.